Progress Against Ovarian Cancer. 1970–1979 Progress Against Ovarian Cancer 1970–1979 1978: First effective combination chemotherapy regimen for ovarian.

Slides:

Advertisements

Similar presentations

Clinical Cancer Advances 2012

Advertisements

Advanced Ovarian Cancer in Practice An Expert Commentary With Justin Chura, MD, MBA A Clinical Context Report.

San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.

Breast Cancer Patient Issues in Family Practice: An Interactive Session.

Major Cancer Milestones

Progress Against Breast Cancer

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Progress Against Lung Cancer. 1970–1979 Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung.

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.

Progress Against Bladder Cancer. Pre-1970 Progress Against Bladder Cancer Pre : Tool offers view inside bladder for first time.

Progress Against Testicular Cancer. 1970–1979 Progress Against Testicular Cancer 1970– : Two new drugs produce first complete remissions in advanced.

Progress Against Cervical Cancer. 1980–1989 Progress Against Cervical Cancer 1980– –1984: HPV virus is discovered to cause cervical cancer.

Progress Against Head and Neck Cancer. 1970–1979.

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970– : FDA approves doxorubicin.

Progress Against Kidney Cancer. 1970–1979 Progress Against Kidney Cancer 1970– : Removing just part of the cancerous kidney is proven safe and.

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Progress Against Liver Cancer. 1970–1979 Progress Against Liver Cancer 1970– : First study finds chemotherapy effective for liver cancer.

Presenter Name(s) Issue date National Student.

Breast Cancer Risk Assessment and Genetic Testing

First cases of AIDS identified.

IRESSA A Case Study in Personalised Medicine Dr Rose McCormack

Through the years… JUNIATA COLLEGE FIELD HOCKEY. SeasonCoachRecord 1973Unknown Jo Reilly Alexa Fultz Alexa Fultz Nancy Harden-Latimore4-4-1.

Update on Ovarian Cancer

From Delft into Almere Prof.dr.ir.Taeke M. de Jong.

History of Biotechnology

Trends in incidence and mortality, England 1989 to 2010.

CANCER SCREENING 2011 DELAWARE CANCER EDUCATION ALLIANCE STEPHEN S. GRUBBS, M.D. HELEN F. GRAHAM CANCER CENTER DELAWARE CANCER CONSORTIUM OCTOBER 5, 2011.

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

What are clinical trials? Phases of Clinical Trials Clinical trials of new medicines are done in phases: Phase I Phase II Phase III.

Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.

Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Medical Achievements Cancer, AIDS, Stem Cell. Cancer Achievements O Newer drugs seem to be making a bigger difference for small, specific groups of patients,

GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

Fallopian Tube and Ovarian Malignancy Schwartz's Principles of Surgery Chapter 41. Gynecology.

1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.

OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True: Clara Natoli.

CA-125 Cancer Antigen-125 Discovered in l981

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

Personal Risk Factors Gender being a woman is the main risk factor for developing breast cancer (100 times more common in women) Age occurrence increase.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.

Clinical Cancer Advances 2010 ASCO’s Annual Report on Progress Against Cancer.

Clinical Cancer Advances 2011 ASCO’s seventh annual Clinical Cancer Advances report identifies this year’s most significant clinical.

Breast and Ovarian Cancer. Symptoms Breast Cancer Ovarian Cancer.

Clinical and Research Updates in Gynecologic Oncology

According to the report, 22% of all cancer deaths are caused due to tobacco. So, it is extremely important to quit consuming tobacco products to prevent.

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy Neil Love, MD1, Kimberly L Blackwell, MD2, Eleftherios.

Oncol Res Treat 2016;39: DOI: /

Family Tree Presentation

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

ARRAY The MILO Study Study Design Schema

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Practical Guidance on the Management of Pan-Negative NSCLC

EVOLUTION OF PARP INHIBITORS IN OVARIAN CANCER

Volume 147, Issue 3, Pages (December 2017)

12th – 13th November GRANADA

Presentation transcript:

Progress Against Ovarian Cancer

1970–1979

Progress Against Ovarian Cancer 1970– : First effective combination chemotherapy regimen for ovarian cancer 1978: Cisplatin approved for advanced ovarian cancer

Progress Against Ovarian Cancer 1980–1989

Progress Against Ovarian Cancer 1980– : Oral contraceptives found to cut ovarian cancer risk

Progress Against Ovarian Cancer 1980–1989 Mid-1980s: Scientists discover ''biomarker'' tied to ovarian cancer – CA-125

Progress Against Ovarian Cancer 1980– : FDA approves carboplatin for ovarian cancer

Progress Against Ovarian Cancer 1990–1999

Progress Against Ovarian Cancer 1990– –1994: Taxanes emerge as vital chemotherapy option for ovarian, breast cancer

Progress Against Ovarian Cancer 1990– : New chemotherapy drug for advanced ovarian cancer

Progress Against Ovarian Cancer 1990–1999 Late 1990s: BRCA1 and BRCA2 gene mutations linked to increased ovarian cancer risk

Progress Against Ovarian Cancer 1990– : FDA approves liposomal doxorubicin for advanced ovarian cancer

Progress Against Ovarian Cancer 2000–Present

Progress Against Ovarian Cancer 2000–Present 2003: New chemotherapy regimen – docetaxel and paclitaxel – provides important treatment option

Progress Against Ovarian Cancer 2000–Present 2005: Researchers work to decode the ovarian cancer genome

Progress Against Ovarian Cancer 2000–Present 2006: Researchers find some ovarian cancers begin in the fallopian tubes 2006: Direct chemotherapy approach increases survival

Progress Against Ovarian Cancer 2000–Present Late 2000s: Researchers identify at least two ovarian cancer subtypes

Progress Against Ovarian Cancer 2000–Present 2009: Preventive surgery confirmed to reduce breast and ovarian cancer risk in women with BRCA gene mutations

Progress Against Ovarian Cancer 2000–Present 2010: Regular CA125 testing to monitor for ovarian cancer recurrence is questioned 2010: Bevacizumab significantly delays progression of advanced ovarian cancer 2010: Pre-surgery chemotherapy proven an effective option for women with advanced ovarian cancer

Progress Against Ovarian Cancer Five-Year Survival Source: National Cancer Institute

Progress Against Ovarian Cancer Mortality Source: National Cancer Institute

Progress Against Ovarian Cancer New Cases Source: National Cancer Institute

Visit CancerProgress.Net for an interactive timeline of progress against a range of common cancers CancerProgress.Net is a project of the American Society of Clinical Oncology, which represents nearly 30,000 physicians who treat people with cancer and research new cures